GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200124415 | Prostate | Tumor | positive regulation of intrinsic apoptotic signaling pathway | 26/3246 | 58/18723 | 1.03e-06 | 1.99e-05 | 26 |
GO:000836015 | Prostate | Tumor | regulation of cell shape | 51/3246 | 154/18723 | 1.42e-06 | 2.56e-05 | 51 |
GO:000854415 | Prostate | Tumor | epidermis development | 89/3246 | 324/18723 | 3.15e-06 | 5.18e-05 | 89 |
GO:003001015 | Prostate | Tumor | establishment of cell polarity | 46/3246 | 143/18723 | 1.09e-05 | 1.56e-04 | 46 |
GO:009016214 | Prostate | Tumor | establishment of epithelial cell polarity | 16/3246 | 31/18723 | 1.38e-05 | 1.89e-04 | 16 |
GO:004340916 | Prostate | Tumor | negative regulation of MAPK cascade | 54/3246 | 180/18723 | 1.92e-05 | 2.50e-04 | 54 |
GO:000734613 | Prostate | Tumor | regulation of mitotic cell cycle | 113/3246 | 457/18723 | 3.37e-05 | 3.96e-04 | 113 |
GO:000991314 | Prostate | Tumor | epidermal cell differentiation | 58/3246 | 202/18723 | 3.99e-05 | 4.60e-04 | 58 |
GO:004349114 | Prostate | Tumor | protein kinase B signaling | 60/3246 | 211/18723 | 4.05e-05 | 4.62e-04 | 60 |
GO:005189613 | Prostate | Tumor | regulation of protein kinase B signaling | 54/3246 | 185/18723 | 4.44e-05 | 5.02e-04 | 54 |
GO:005105112 | Prostate | Tumor | negative regulation of transport | 114/3246 | 470/18723 | 7.43e-05 | 7.82e-04 | 114 |
GO:005127114 | Prostate | Tumor | negative regulation of cellular component movement | 92/3246 | 367/18723 | 1.03e-04 | 9.99e-04 | 92 |
GO:200014614 | Prostate | Tumor | negative regulation of cell motility | 89/3246 | 359/18723 | 1.99e-04 | 1.74e-03 | 89 |
GO:004578611 | Prostate | Tumor | negative regulation of cell cycle | 93/3246 | 385/18723 | 3.79e-04 | 2.95e-03 | 93 |
GO:004001313 | Prostate | Tumor | negative regulation of locomotion | 94/3246 | 391/18723 | 4.20e-04 | 3.21e-03 | 94 |
GO:003033613 | Prostate | Tumor | negative regulation of cell migration | 84/3246 | 344/18723 | 4.95e-04 | 3.66e-03 | 84 |
GO:00991111 | Prostate | Tumor | microtubule-based transport | 51/3246 | 190/18723 | 6.62e-04 | 4.68e-03 | 51 |
GO:004593011 | Prostate | Tumor | negative regulation of mitotic cell cycle | 60/3246 | 235/18723 | 9.42e-04 | 6.18e-03 | 60 |
GO:003017813 | Prostate | Tumor | negative regulation of Wnt signaling pathway | 46/3246 | 170/18723 | 9.84e-04 | 6.37e-03 | 46 |
GO:003085911 | Prostate | Tumor | polarized epithelial cell differentiation | 11/3246 | 24/18723 | 1.13e-03 | 7.23e-03 | 11 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa050201 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa048101 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa050202 | Colorectum | SER | Prion disease | 119/1580 | 273/8465 | 4.61e-22 | 3.06e-20 | 2.22e-20 | 119 |
hsa048102 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
hsa050203 | Colorectum | SER | Prion disease | 119/1580 | 273/8465 | 4.61e-22 | 3.06e-20 | 2.22e-20 | 119 |
hsa048103 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
hsa050204 | Colorectum | MSS | Prion disease | 129/1875 | 273/8465 | 1.04e-20 | 5.00e-19 | 3.06e-19 | 129 |
hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
hsa048104 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
hsa050205 | Colorectum | MSS | Prion disease | 129/1875 | 273/8465 | 1.04e-20 | 5.00e-19 | 3.06e-19 | 129 |
hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
hsa048105 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C9 | SNV | Missense_Mutation | | c.706N>C | p.Asn236His | p.N236H | P02748 | protein_coding | deleterious(0.03) | benign(0.005) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
C9 | SNV | Missense_Mutation | novel | c.1150N>A | p.His384Asn | p.H384N | P02748 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C9 | SNV | Missense_Mutation | novel | c.1483N>C | p.Glu495Gln | p.E495Q | P02748 | protein_coding | deleterious(0.03) | probably_damaging(0.989) | TCGA-BH-A0B0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
C9 | SNV | Missense_Mutation | | c.1280C>T | p.Ser427Leu | p.S427L | P02748 | protein_coding | deleterious(0.02) | possibly_damaging(0.879) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
C9 | SNV | Missense_Mutation | | c.163N>T | p.Asp55Tyr | p.D55Y | P02748 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C9 | insertion | Frame_Shift_Ins | novel | c.6_7insT | p.Ala3CysfsTer26 | p.A3Cfs*26 | P02748 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
C9 | insertion | In_Frame_Ins | novel | c.5_6insCTGGGACTACCATAACAAAGCACCACAAGCTGG | p.Ser2_Ala3insTrpAspTyrHisAsnLysAlaProGlnAlaGly | p.S2_A3insWDYHNKAPQAG | P02748 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
C9 | deletion | Frame_Shift_Del | | c.1481delN | p.Leu494TrpfsTer14 | p.L494Wfs*14 | P02748 | protein_coding | | | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
C9 | insertion | Nonsense_Mutation | novel | c.122_123insGTGAGGATGCTGAGGATGACTGCGGAA | p.Ile41delinsMetTerGlyCysTerGlyTerLeuArgLys | p.I41delinsM*GC*G*LRK | P02748 | protein_coding | | | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
C9 | SNV | Missense_Mutation | novel | c.1294G>A | p.Gly432Arg | p.G432R | P02748 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |